|
1
|
Savitsky D, Tamura T, Yanai H and
Taniguchi T: Regulation of immunity and oncogenesis by the IRF
transcription factor family. Cancer Immunol Immunother. 59:489–510.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takaoka A, Yanai H, Kondo S, Duncan G,
Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW and
Taniguchi T: Integral role of IRF-5 in the gene induction programme
activated by Toll-like receptors. Nature. 434:243–249. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yanai H, Chen HM, Inuzuka T, Kondo S, Mak
TW, Takaoka A, Honda K and Taniguchi T: Role of IFN regulatory
factor 5 transcription factor in antiviral immunity and tumor
suppression. Proc Natl Acad Sci USA. 104:3402–3407. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krausgruber T, Saliba D, Ryzhakov G,
Lanfrancotti A, Blazek K and Udalova IA: IRF5 is required for
late-phase TNF secretion by human dendritic cells. Blood.
115:4421–4430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barnes BJ, Kellum MJ, Field AE and Pitha
PM: Multiple regulatory domains of IRF-5 control activation,
cellular localization, and induction of chemokines that mediate
recruitment of T lymphocytes. Mol Cell Biol. 22:5721–5740. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng D, Stone RC, Eloranta ML,
Sangster-Guity N, Nordmark G, Sigurdsson S, Wang C, Alm G, Syvänen
AC, Rönnblom L and Barnes BJ: Genetic variants and
disease-associated factors contribute to enhanced interferon
regulatory factor 5 expression in blood cells of patients with
systemic lupus erythematosus. Arthritis Rheum. 62:562–573.
2010.PubMed/NCBI
|
|
7
|
Kim K, Cho SK, Han TU, Kim JH, Kang SJ,
Kang C and Bae SC: A redundant epistatic interaction between IRF5
and STAT4 of the type I interferon pathway in susceptibility to
lupus and rheumatoid arthritis. Lupus. 22:1336–1340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lessard CJ, Li H, Adrianto I, Ice JA,
Rasmussen A, Grundahl KM, Kelly JA, Dozmorov MG, Miceli-Richard C,
Bowman S, et al: Variants at multiple loci implicated in both
innate and adaptive immune responses are associated with Sjögren's
syndrome. Nat Genet. 45:1284–1292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stone RC, Feng D, Deng J, Singh S, Yang L,
Fitzgerald-Bocarsly P, Eloranta ML, Rönnblom L and Barnes BJ:
Interferon regulatory factor 5 activation in monocytes of systemic
lupus erythematosus patients is triggered by circulating
autoantigens independent of type I interferons. Arthritis Rheum.
64:788–798. 2012. View Article : Google Scholar :
|
|
10
|
Barnes BJ, Kellum MJ, Pinder KE, Frisancho
JA and Pitha PM: Interferon regulatory factor 5, a novel mediator
of cell cycle arrest and cell death. Cancer Res. 63:6424–6431.
2003.PubMed/NCBI
|
|
11
|
Bi X, Feng D, Korczeniewska J, Alper N, Hu
G and Barnes BJ: Deletion of Irf5 protects hematopoietic stem cells
from DNA damage-induced apoptosis and suppresses
γ-irradiation-induced thymic lymphomagenesis. Oncogene.
33:3288–3297. 2014. View Article : Google Scholar
|
|
12
|
Hu G and Barnes BJ: IRF-5 is a mediator of
the death receptor-induced apoptotic signaling pathway. J Biol
Chem. 284:2767–2777. 2009. View Article : Google Scholar
|
|
13
|
Massimino M, Consoli ML, Mesuraca M,
Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond
HM, et al: IRF5 is a target of BCR-ABL kinase activity and reduces
CML cell proliferation. Carcinogenesis. 35:1132–1143. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamashita M, Toyota M, Suzuki H, Nojima M,
Yamamoto E, Kamimae S, Watanabe Y, Kai M, Akashi H, Maruyama R, et
al: DNA methylation of interferon regulatory factors in gastric
cancer and noncancerous gastric mucosae. Cancer Sci. 101:1708–1716.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bi X, Hameed M, Mirani N, Pimenta EM,
Anari J and Barnes BJ: Loss of interferon regulatory factor 5
(IRF5) expression in human ductal carcinoma correlates with disease
stage and contributes to metastasis. Breast Cancer Res.
13:R1112011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Massimino M, Vigneri P, Fallica M, Fidilio
A, Aloisi A, Frasca F and Manzella L: IRF5 promotes the
proliferation of human thyroid cancer cells. Mol Cancer. 11:212012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kreher S, Bouhlel MA, Cauchy P, Lamprecht
B, Li S, Grau M, Hummel F, Köchert K, Anagnostopoulos I, Jöhrens K,
et al: Mapping of transcription factor motifs in active chromatin
identifies IRF5 as key regulator in classical Hodgkin lymphoma.
Proc Natl Acad Sci USA. 111:E4513–E4522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mancl ME, Hu G, Sangster-Guity N,
Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P, Pitha PM, Pinder K
and Barnes BJ: Two discrete promoters regulate the alternatively
spliced human interferon regulatory factor-5 isoforms. Multiple
isoforms with distinct cell type-specific expression, localization,
regulation, and function. J Biol Chem. 280:21078–21090. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Graham RR, Kozyrev SV, Baechler EC, Reddy
MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano
MF; Argentine and Spanish Collaborative Groups; et al: A common
haplotype of interferon regulatory factor 5 (IRF5) regulates
splicing and expression and is associated with increased risk of
systemic lupus erythematosus. Nat Genet. 38:550–555. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sigurdsson S, Göring HH, Kristjansdottir
G, Milani L, Nordmark G, Sandling JK, Eloranta ML, Feng D,
Sangster-Guity N, Gunnarsson I, et al: Comprehensive evaluation of
the genetic variants of interferon regulatory factor 5 (IRF5)
reveals a novel 5 bp length polymorphism as strong risk factor for
systemic lupus erythematosus. Hum Mol Genet. 17:872–881. 2008.
View Article : Google Scholar
|
|
21
|
Briggs MR, Kadonaga JT, Bell SP and Tjian
R: Purification and biochemical characterization of the
promoter-specific transcription factor, Sp1. Science. 234:47–52.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Seznec J, Silkenstedt B and Naumann U:
Therapeutic effects of the Sp1 inhibitor mithramycin A in
glioblastoma. J Neurooncol. 101:365–377. 2011. View Article : Google Scholar
|
|
24
|
Xu HG, Jin R, Ren W, Zou L, Wang Y and
Zhou GP: Transcription factors Sp1 and Sp3 regulate basal
transcription of the human IRF-3 gene. Biochimie. 94:1390–1397.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren W, Zhu LH, Xu HG, Jin R and Zhou GP:
Characterization of a spliced variant of human IRF-3 promoter and
its regulation by the transcription factor Sp1. Mol Biol Rep.
39:6987–6993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clark DN, Read RD, Mayhew V, Petersen SC,
Argueta LB, Stutz LA, Till RE, Bergsten SM, Robinson BS, Baumann
DG, et al: Four promoters of IRF5 respond distinctly to stimuli and
are affected by autoimmune-risk polymorphisms. Front Immunol.
4:3602013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kadonaga JT, Carner KR, Masiarz FR and
Tjian R: Isolation of cDNA encoding transcription factor Sp1 and
functional analysis of the DNA binding domain. Cell. 51:1079–1090.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suske G: The Sp-family of transcription
factors. Gene. 238:291–300. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suske G, Bruford E and Philipsen S:
Mammalian SP/KLF transcription factors: Bring in the family.
Genomics. 85:551–556. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Philipsen S and Suske G: A tale of three
fingers: The family of mammalian Sp/XKLF transcription factors.
Nucleic Acids Res. 27:2991–3000. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tan NY and Khachigian LM: Sp1
phosphorylation and its regulation of gene transcription. Mol Cell
Biol. 29:2483–2488. 2009. View Article : Google Scholar : PubMed/NCBI
|
